Physician profile
Michael Claussen
NPI 1487144473
$561.65
in general payments reported to CMS, 2019-2025
15 companies · $14.60 in 2025
The $14.60 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.09 · 2022: $51.03 · 2023: $196 · 2024: $286 · 2025: $14.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $133.08 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $64.87 | 2023-2024 | |
| Pfizer INC. | $63.21 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $54.98 | 2023-2024 | Airsupra, Farxiga |
| Astellas Pharma US INC | $39.39 | 2023 | Veozah |
| Abbvie INC. | $36.10 | 2024 | |
| Glaxosmithkline, LLC. | $32.51 | 2024 | Trelegy Ellipta, Arexvy |
| Lucid Diagnostics INC. | $21.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.46 | 2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $17.81 | 2023 | |
| Acadia Pharmaceuticals INC | $17.43 | 2024 | Daybue |
| Sanofi Pasteur INC. | $17.39 | 2023 | |
| Janssen Pharmaceuticals, INC | $16.16 | 2023 | Spravato |
| Fresenius USA Marketing, INC. | $14.09 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.06 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Claussen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.